PREVENTION OF AUTOIMMUNE DIABETES (GPPAD)
WITHOUT TYPE 1 DIABETES
Joint Effort across Europe.
Welcome to our Sites.
Lead investigator:
Prof. Anette-Gabriele Ziegler & Dr Christiane Winkler
Phone: 00800-33 15 33 15
Email: cc@gppad.org
Lead investigator:
Prof. Ezio Bonifacio & Prof. Dr Reinhard Berner
Phone: 0800-72 45 148
Email: diabetesstudie.crtd@tu-dresden.de
Lead investigator:
Prof. Dr Olga Kordonouri & Prof. Dr Thomas Danne
Phone: 0800-37 33 37 15
Email: freder1k@hka.de
Lead investigator:
Prof. Kristina Casteels
Phone: +32-(0)-16-348554
Email: freder1kstudie@uzleuven.be
Lead investigator:
Prof. Steve Robson & Dr Catherine Owen
Phone: +44-(0)-191-2820553
Email: sharon.king10@nhs.net
Lead investigator:
Dr Agnieszka Szypowska & Dr Mariusz Ołtarzewski
Phone: +48-(0)-22 317 94 44
Email: kontakt@swiatbezjedynki.pl
Lead investigator:
Prof. Helena Elding Larsson & Prof. Dr Markus Lundgren
Phone: +46-(0)-40-39 11 33
Email: gppad@med.lu.se
Lead investigator:
Dr. Rachel Besser
Phone: +44-(0)-1865-572258
Email: INGR1D@wrh.ox.ac.uk
Lead investigator:
Heikki Hyöty
Phone: +358-50-5168480
Email: heikki.hyoty@tuni.fi
Lead investigator:
Encarnita Mariotti-Ferrandiz
Email: encarnita.mariotti@sorbonne-universite.fr
Lead investigator:
Timothy Tree
Email: timothy.tree@kcl.ac.uk
Lead investigator:
Margarita Dominguez-Villar
Email: m.dominguez-villar@imperial.ac.uk
Lead investigator:
Kathleen Gillespie
Email: K.M.Gillespie@bristol.ac.uk
Lead investigator:
Tomi Pastinen
Email: tpastinen@cmh.edu
-
Dr. Agnieszka Szypowska | Warszawa, Poland -
Prof. Dr. Helena Elding Larsson | Malmö, Sweden -
Prof. Dr. Kristina Casteels | Leuven, Belgium -
Dr. Mariusz Ołtarzewski | Warszawa, Poland -
Prof. Dr. Anette-Gabriele Ziegler | Munich, Germany -
Prof. Dr. Steve Robson | Newcastle, UK -
Prof. Dr. Enzio Bonifacio | Saxony, Germany -
Prof. Dr. Markus Lundgren | Malmö, Sweden -
Prof. Dr. Olga Kordonouri | Hanover, Germany
WHAT IS GPPAD?
Preventing Type 1 Diabetes together.
The Global Platform for the Prevention of Autoimmune Diabetes (GPPAD) was established in 2017 as a consortium of European research institutions. It aims to facilitate a coordinated, multidisciplinary approach to genetic screening and the conduct of primary prevention studies for type 1 diabetes. The overarching goal of GPPAD studies is to significantly reduce the incidence of islet autoimmunity and type 1 diabetes in children. To achieve this, clinical research sites from Belgium (Leuven), Germany (Dresden, Hanover, Munich), Poland (Warsaw), Sweden (Malmö), and the United Kingdom (Oxford, Cambridge, Newcastle) collaborate.
OVER 500,000 EUROPEAN CHILDREN ARE IN.
Our Screenings and Studies.
GPPAD conducts newborn screening in the general population to identify infants at high genetic risk of developing islet autoimmunity and type 1 diabetes. GPPAD investigators provide expert counseling to these families and invites them to participate in primary prevention studies. To date, over 500,000 infants have undergone screening, and more than 2,000 children are participating in the GPPAD prevention studies, POInT, SINT1A, and AVAnT1A. GPPAD also encompasses expert groups for celiac disease and allergy research.
SHARING DATA TO DRIVE INNOVATIONS.
Repository for biospecimen and data.
Furthermore, GPPAD provides researchers worldwide with the opportunity to conduct innovative research on biospecimens from the GPPAD studies, aiming to make significant advances in the study of the etiology, pathogenesis, and prevention of type 1 diabetes and other immune-mediated diseases.
JOINT EUROPEAN EFFORT.
Coordinated from Munich.
The GPPAD coordination center is situated at the Institute of Diabetes Research at Helmholtz Munich, with the Klinikum rechts der Isar of the Technical University of Munich acting as the sponsor for clinical trials in GPPAD.